glp-1 receptor agonists and cancer risk in adults with obesity agonist use obese nondiabetic Study Finds GLP-1 Receptor Agonists
Description
Approved doses of oral semaglutide range from 3 mg to 14 mg and subcutaneous semaglutide doses range from 0.25 mg to 2.4 mg, with higher doses being used for weight loss rather than glycemic control
Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men
Accessed 3 Nov 2025
E., Waldner, R
Front Cell Dev Biol 2020;8:602574.ArticlePubMedPMC 38
Treatment of primary neonatal mouse cardiomyocytes with liraglutide increases cAMP formation and reduces apoptosis, as indicated by inhibition of TNFa induction of caspase 3 activity [614]
